Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy.

Advanced science (Weinheim, Baden-Wurttemberg, Germany) - 1 Sept 2025

Gu Yuanzhuo, He Hongchao, Qiao Shilei, Shao Yifan, Wang Lurong, Zhang Zhengkui, Zhang Long, Zhou Fangfang

Abstract excerpt

The success of immune checkpoint blockades (ICBs) has accelerated the clinical implementation of multiple single agents and combination immunotherapies, but the response rates vary. Reconsideration of immune-oncology therapeutic failures via perspective from tumor-intrinsic (such as oncogenic driver genes) and tumor-extrinsic (the complexity of immune cell-cancer cell interactions) may help to better design more...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ErbB Receptors
Share to EGFR gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Lung Cancer Treatments and Mutations

Share to Mutation

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 40859900
DOI: 10.1002/advs.202505785
PMCID: PMC12462975

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy.PMID 40859900Read ↗

Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023?Semantic proximity Read ↗

Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor.Semantic proximity Read ↗

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?Semantic proximity Read ↗

Epidermal growth factor receptor mutations in breast Cancer: Therapeutic challenges and way forward.Semantic proximity Read ↗

EGFR mutations and abnormal trafficking in cancers.Semantic proximity Read ↗

Immunotherapy in EGFR-TKI-resistant NSCLC: Mechanisms, therapeutic strategies, and emerging challenges.Semantic proximity Read ↗

Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.Semantic proximity Read ↗

Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.Semantic proximity Read ↗

Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers.Semantic proximity Read ↗

The epidermal growth factor receptor pathway: a model for targeted therapy.Semantic proximity Read ↗

EGFR signaling pathway as therapeutic target in human cancers.Semantic proximity Read ↗

EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired ResistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.